Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.
Authors
Zubairi, IDean, Emma J
Molife, L
Ranson, Malcolm R
El-Khouly, F
Savulsky, C
Reyderman, L
Jia, Y
Hutton, E
Morrison, R
Sweeting, L
Greystoke, A
Barriuso, J
Kristeleit, R
Evans, T
Affiliation
Beatson West Scotland Cancer Center, Glasgow, Lanark, ScotlandIssue Date
2017